Story · Medicine & Biotech

New Safety Labeling Added to GLP-1 Receptor Agonists Over NAION Risk

2 outlets · first reported by EMJ Reviews on · latest · 34 hours of coverage · 2 countries

Coverage, in order

  1. Medical Dialogues India obscure study observationalpeer-reviewed
    GLP-1 Receptor Agonists Linked to Lower Risk of Obesity-Related Cancers: JAMA

    USA: A large retrospective cohort analysis has found that GLP-1 receptor agonists were associated with a lower risk of obesity-related cancers compared with insulin and sulfonylureas in patients with diabetes. However, cancer risk did not differ significantly compared with metformin, DPP-4…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.